Výsledky vyhledávání - "Donna Vickery"

MK-6482, a hypoxia-inducible factor 2α inhibitor (HIF-2α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study

Autor: Donna Vickery, Li Fan, Toni K. Choueiri, Thomas Powles, Rodolfo F. Perini, Brian I. Rini, Laurence Albiges

Publikováno v: Journal of Clinical Oncology. 39:TPS368-TPS368

TPS368 Background: In ccRCC, HIF-2α is involved in the activation of genes such as VEGFA, cyclin D1, and CXCR4, which are associated with angiogenesis, tumor progression, and metastasis. HIF-2α can accumulate and be overactivated due to the inactiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ef5c4409fd20499a4d350812b32cb7c
https://doi.org/10.1200/jco.2021.39.6_suppl.tps368

Zobrazit plný text záznamu

Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC)

Autor: Toni K. Choueiri, Todd Michael Bauer, David F. McDermott, Edward Arrowsmith, Ananya Roy, Rodolfo F. Perini, Donna Vickery, Scott S. Tykodi

Publikováno v: Journal of Clinical Oncology. 39:272-272

272 Background: Belzutifan (MK-6482) inhibits HIF-2α and demonstrated antitumor activity and favorable safety as monotherapy in a phase 1 study of patients (pts) with metastatic ccRCC. Current study (NCT03634540) investigates belzutifan plus cabozan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cd1e70c769772734c2f0e76ee7cc9477
https://doi.org/10.1200/jco.2021.39.6_suppl.272

Zobrazit plný text záznamu

Lack of Pharmacokinetic Drug Interaction Between Oral Posaconazole and Caspofungin or Micafungin

Autor: Gopal Krishna, Eric Beresford, Xin Yu, Lei Ma, Edward Power, Donna Vickery, Matthew Medlock, Carl Noren

Publikováno v: The Journal of Clinical Pharmacology. 51:84-92

The objective of this phase 1, open-label, parallel, randomized study was to determine the effect of posaconazole on the pharmacokinetics of caspofungin and micafungin in 67 healthy subjects. Caspofungin (70 mg on day 1, 50 mg on days 2-14 once daily

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef7adad1832131da28e1524ae5446e71
https://doi.org/10.1177/0091270009360982

Zobrazit plný text záznamu

Skin concentrations and pharmacokinetics of posaconazole after oral administration

Autor: Gopal Krishna, Eric Beresford, Xin Yu, Donna Vickery, Monika Martinho, Amir Tavakkol, Steven Komjathy, Lei Ma

Publikováno v: Antimicrobial agents and chemotherapy. 54(5)

A randomized, single-center, open-label study of posaconazole (POS) was performed to determine the concentration of POS in the skin of 30 healthy adult human subjects receiving 400 mg POS oral suspension twice daily for 8 days with a high-fat meal. B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::918ae61ccb13097468d31f62f11e89e2
https://pubmed.ncbi.nlm.nih.gov/20194702

Zobrazit plný text záznamu

Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers

Autor: Xin Yu, Irene Wu, Lei Ma, Steven Komjathy, Eric Beresford, Edward Power, Gopal Krishna, Donna Vickery

Publikováno v: Antimicrobial agents and chemotherapy. 53(11)

The aim of this single-center, phase 1, randomized, 5 by 5 crossover, open-label study was to determine the effects of varying amounts of a nutritional supplement (Boost Plus) on the pharmacokinetics of posaconazole in 30 healthy volunteers. After an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7906b1b0f38b81af671a5f36cfebea6
https://pubmed.ncbi.nlm.nih.gov/19738015

Zobrazit plný text záznamu

Akademický článek

KCRS Kidney Cancer Research Summit ACCELERATING CURES.

Publikováno v: Oncologist; 2024 Supplement, Vol. 29, pS1-S37, 97p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání